ArticleJournal of medical cases2022
Acquired Hemophilia A Developed Post COVID-19 Vaccine: An Extremely Rare Complication.
Article in Journal of medical cases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Acquired hemophilia A following SARS-CoV-2 infection and vaccination: clinical summary and insights.Journal of thrombosis and haemostasis : JTH · 2026Pooled it
- Adult-onset Vitamin K-dependent Coagulation Factor Deficiency of Unidentified Etiology.Internal medicine (Tokyo, Japan) · 2026Article
- Article
- Acquired Hemophilia A after SARS-CoV-2 Immunization: A Narrative Review of a Rare Side Effect.Vaccines · 2024Review
- Acquired Hemophilia A Diagnosed Based on Gross Hematuria: A Case Report and Literature Review.Case reports in urology · 2024Article
- Hematological Complications in a COVID-19 Patient: A Case Report.Diseases (Basel, Switzerland) · 2023Article
- Blood Coagulation and Thrombotic Disorders following SARS-CoV-2 Infection and COVID-19 Vaccination.Biomedicines · 2023Review
- Article
- Acquired Hemophilia A: An Update on the Etiopathogenesis, Diagnosis, and Treatment.Diagnostics (Basel, Switzerland) · 2023Review
- Does SARS-CoV-2vaccination induce acquired autoimmune discords and inflammatory manifestations?Clinics (Sao Paulo, Brazil) · 2023Article
- Acute-type acquired hemophilia A after COVID-19 mRNA vaccine administration: A new disease entity?Journal of autoimmunity · 2022Article
- Acquired hemophilia A secondary to SARS-CoV-2 pneumonia: a case report.Biochemia medica · 2022Article
- Acquired hemophilia following COVID-19 vaccination: Case report and review of literature.Research and practice in thrombosis and haemostasis · 2022Article
- Current Evidence in SARS-CoV-2 mRNA Vaccines and Post-Vaccination Adverse Reports: Knowns and Unknowns.Diagnostics (Basel, Switzerland) · 2022Review
- Acquired Hemophilia A After SARS-CoV-2 Infection: A Case Report.Journal of medical cases · 2022Article
- Case Report: Acquired Haemophilia A Following mRNA-1273 Booster Vaccination Against SARS-CoV-2 With Concurrent Diagnosis of Pleomorphic Dermal Sarcoma.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder caused by circulating autoantibodies (inhibitor) directed against coagulation factor VIII (FVIII). We report a 39-year-old single female who presented to emergency department with sudden onset gross hematuria 10 days following her first dose of Pfizer-BioNTech severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA (coronavirus disease 2019 (COVID-19)) vaccine. Coagulation profile revealed isolated prolongation of the activated partial thromboplastin time due to FVIII deficiency with normal von Willebrand factor and activity. Mixing study revealed time-dependent inhibitor pattern that was successively identified as directed against FVIII using the Nijmegen-modified Bethesda assay. FVIII inhibitor in a titer of 17.2 Bethesda Units/mL was detected. While thrombosis is a frequent complication of severe COVID-19 infection, on the other hand, bleeding is rare in the setting of COVID-19 infection/vaccination with no anticoagulants. Till date, a couple of cases of acquired hemophilia developed after receiving mRNA derived COVID-19 vaccines (Pfizer-BioNTech SARS-CoV-2 mRNA vaccine and Moderna mRNA vaccines) had been reported. It is important to raise the awareness about this rare side effect that might be directly induced by the mRNA COVID-19 vaccine or that the vaccine could have triggered it in a genetically predisposed individual. We recommend considering screening for an inhibitor (by mixing study) in cases with otherwise unexplained onset hemorrhagic disorder and/or isolated activated partial thromboplastin time prolongation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.